News ResMed, Inc.

Equities

RMD

US7611521078

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 21:00:02 05/12/2025 GMT			5-day change	1st Jan Change
256.55 ^USD	+2.00%		+0.28%	+12.18%

12-04	Resmed Insider Sold Shares Worth $502,940, According to a Recent SEC Filing	MT
12-02	LivaNova PLC Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea, Effective December 1, 2025	CI

Resmed Insider Sold Shares Worth $502,940, According to a Recent SEC Filing	12-04	MT
LivaNova PLC Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea, Effective December 1, 2025	12-02	CI
Major Breakthrough in At Home Sleep Therapy: ResMed Launches "AirCurve 11 VAuto" to Improve Sleep Apnea Treatment Comfort and Compliance	11-28	AQ
ResMed Inc. Announces Not Seek Re-Election of Richard Sulpizio to the Board of Directors, Effective November 19, 2025	11-25	CI
UK financial sector makes slow progress on preparations for new settlement system	11-25	RE
ResMed : Statement of Changes in Beneficial Ownership (Form 4)	11-24	PU
ResMed : Statement of Changes in Beneficial Ownership (Form 4)	11-24	PU
ResMed : Statement of Changes in Beneficial Ownership (Form 4)	11-24	PU
Ex-dividend day	11-12	FA
ResMed Insider Sold Shares Worth $2,000,773, According to a Recent SEC Filing	11-11	MT
ResMed CFO Sells Shares	11-05	MT
ResMed CFO Buys, Sells Shares	11-05	MT
Resmed Insider Sold Shares Worth $742,620, According to a Recent SEC Filing	11-04	MT
ResMed CFO Sells Shares	11-03	MT
ASX Biggest Losers	11-03	MT
ASX Midday Sector Update: Information Technology Stocks Rise, Healthcare Down	11-03	MT
Baird Adjusts Price Target on ResMed to $300 From $320	10-31	MT
Jefferies & Co Adjusts ResMed Price Target to $285 From $290	10-31	MT
Wells Fargo Adjusts ResMed Price Target to $265 From $280	10-31	MT
Wolfe Research Adjusts ResMed Price Target to $225 From $215	10-31	MT
Morgan Stanley Adjusts ResMed Price Target to $305 From $304	10-31	MT
Mizuho Adjusts Price Target on ResMed to $300 From $310	10-31	MT
KeyBanc Adjusts Price Target on ResMed to $299 From $298	10-31	MT
RBC Lifts Price Target on ResMed to $303 From $300, Keeps Outperform Rating	10-31	MT
Morgan Stanley Lifts Price Target on ResMed to $305 From $304, Keeps Overweight Rating	10-31	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ResMed's innovation-driven success and prospects

October 31, 2025 at 08:55 am